Research News

FDA Approves First Drug for Neurological Symptoms of Type 3 Gaucher Disease

Amara Diallo · Science Communicator

November 19, 2026 · 1 min read

Source: FDA DrugsRead original →

The FDA has approved Infilbray (venglustat) tablets for the neurological symptoms of Type 3 Gaucher disease (GD3) in adults and children weighing at least 15 kg, according to an FDA press announcement. This marks the first approved therapy specifically targeting the brain related symptoms of this rare inherited condition.

GD3 occurs when the body cannot properly break down fatty molecules called glucosphingolipids due to a faulty enzyme. Unlike Type 1 Gaucher disease, GD3 also affects the brain, causing progressive problems with balance, coordination, speech, memory, and thinking. Infilbray is a glucosylceramide synthase inhibitor that crosses the blood brain barrier to reduce buildup of these harmful substances, including within the brain.

The approval rests on a randomized, double blind, multicenter trial of 43 patients aged 12 and older with GD3 who had already reached systemic stabilization on enzyme replacement therapy. Participants took oral Infilbray daily or continued intravenous enzyme replacement every two weeks for 52 weeks. Those on Infilbray showed improvement on a combined measure of ataxia and cognitive function compared to the enzyme replacement group.

Reported side effects include gastrointestinal symptoms and mood changes, with serious psychiatric risks such as suicidal ideation noted in labeling. Animal studies flagged possible effects on vision in younger patients and on fetal development. The drug received Orphan Drug designation and Priority Review before this approval to Genzyme, a Sanofi company.

This article is for education only. It is not medical advice. Compounds discussed here are sold for research purposes. Talk to a licensed clinician before making health decisions.

Ready to explore peptides?

Browse every compound profile or work out your dose with the reconstitution calculator.

Laboratory research use only

All compounds and information on this site are intended strictly for laboratory research and educational use only. They are not for human or veterinary use.

The statements on this website have not been evaluated by the U.S. Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure, or prevent any disease.

Educational use only. The information and calculators on this site are provided for research and educational purposes and are not medical advice, a diagnosis, a prescription, or a substitute for a licensed healthcare provider. Many compounds described are research compounds or prescription medicines not approved for general use. You must be 21 or older. Always consult a qualified clinician before making any health decision. Read the full disclaimer · Privacy Policy

© 2026 LifeConverted. All rights reserved.

Not for human or veterinary use.

Powered with by Plondo